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INTRODUCTION
Prostate cancer is a significant public health issue. The reported incidence of prostate cancer doubled Internal Medicine Journal 2002; 32: 215-223 between 1985 and 1994 with the introduction of more intensive medical surveillance using prostate specific antigen (PSA) and other tests. 1 Debate about testing for prostate cancer using PSA and digital rectal examination (DRE) continues. 2, 3 The majority of evidence-based reviews indicate that evidence of benefit from screening for prostate cancer using PSA testing is inconclusive. 4, 5 This doubt is expected to remain for the next 5 to 10 years. 4, 5 It is also unclear how PSA can be most effectively used in the detection of prostate cancer. 2 However, large population-based studies have shown increased survival benefits in the early treatment of prostate cancer when compared with no active therapy in men with moderately and poorly differentiated disease. 6 The Australian Health Technology Advisory Committee (AHTAC) 1 recommends that men without symptoms should not be screened for prostate cancer due to a lack of positive evidence about the efficacy of the tests and treatments for prostate cancer. Men who are offered, or who request a PSA or similar test should be fully informed of its limitations. In addition, consumers should be aware of their potential involvement in further diagnostic and treatment choices resulting from the testing process. 1 Given the lack of consensus on prostate cancer testing, it is particularly important that consumers understand the issues in a way that will permit them to decide whether or not to have a PSA test or, if symptomatic, how their condition is managed. It is evident that men who simply follow professional advice could be managed in vastly different ways, depending upon which doctor they consult. The AHTAC recommended that men being offered or requesting a PSA test must be fully informed of the limitations of the available tests and of the possible further diagnostic and treatment choices they may face if they decide to proceed with an initial test. 1 High levels of prostate cancer testing occur in the Australian community. In 1996, costs of $A10 million were incurred by fees charged for PSA and prostatic acid phosphatase tests. 7, 8 This could be attributed to tests for men with symptoms or for monitoring patients with prostate cancer who have undergone therapy. Alternatively, it could be attributed to requests for prostate cancer tests from members of the asymptomatic population, who may not be fully informed of the speculative and controversial nature of the test and may not have an awareness of treatment options and their effectiveness. 9 In the absence of overwhelming evidence in favour of regular testing for prostate cancer, there are also short-term economic disincentives to do so. 10 The aim of this research was to assess the attitudes and testing experiences associated with prostate cancer testing among male doctors (MD) who had reached an age at which they themselves were at risk of prostate cancer, and to compare their views with those of a sample of men in the community in the same age group. MD were selected as the comparison group as they are presumed to be well-informed health consumers and, as a result, their attitudes, practices and personal experience with prostate cancer testing could be a good indicator of what an informed population might think and do.
METHODS

Male doctors (MD)
A survey was conducted on 266 (62%) MD, generated from a random selection of 430 male practitioners aged between 49 and 71 years who were contactable from the Medical Register of Victoria. The survey was conducted over a 4-week period between April and May 1997. Twenty pilot interviews were conducted to pre-test the survey. The primary method was telephone surveying, although some doctors elected to complete a written survey. Telephone numbers were obtained from White Pages OnLine (Telstra Corporation, Australia). Up to eight callbacks were attempted in order to maximize participation. Five experienced interviewers conducted telephone interviews, which averaged 5-10 min in duration. The main reasons for non-participation were: (i) no response to repeated telephone calls to the practice (43%), (ii) retired (13%), (iii) too busy (13%) or (iv) overseas (9%).
Approximately one-third of the MD approached stated that they would only complete the survey if it were in a written format. In an attempt to keep the response rate at an acceptable level, these doctors were offered the option of completing a written version of the questionnaire. The telephone survey was adapted into a self-completion format. To optimize participation, many of the open-ended questions that were included in the telephone survey were omitted. Both the mail and telephone surveys covered five main subject areas: (i) sources of knowledge on prostate cancer, (ii) attitudes towards prostate cancer testing, (iii) whether tested for prostate cancer, (iv) professional practice with prostate cancer testing and (v) recall on urinary symptoms experienced. 2002; 32: 215-223 Of the 112 surveys sent out, 69 (61%) were completed and returned. A minimum of two follow ups was made to inquire about non-returns. No significant differences on the variables age, marital status and area of work were found between those who responded by telephone (n = 197) and those who completed the mail survey (n = 69). The two groups were therefore collapsed for analysis.
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Community sample (CS)
The sample was generated through a random selection of telephone numbers from White Pages OnLine for the state of Victoria. A total of 3529 telephone numbers were dialled to obtain a final sample of 500 (47% participation rate) men who met the selection criteria (i.e. were aged ≥ 49 years of age and were English speaking (n = 1057)). No information was collected on non-respondents, consequently selection bias could not be ascertained.
Twenty-four pilot interviews were conducted to pretest the survey questionnaire. The main survey was conducted over a 3-week period between January and February 1997.
Ethics
Ethics approval was received from the Anti-Cancer Council of Victoria and all respondents gave informed consent to participate in the survey.
Sample size and statistical analyses
To derive a more precise indication of knowledge and attitudes among men, the CS was over-sampled compared to the doctor's survey.
Data collected from the survey were analysed using SPSS (Statistical Package for the Social Sciences, SPSS Statistical Algorithms, SPSS Inc., Chicago, IL, USA). Descriptive statistics were used to characterize the sample. Statistical tests for univariate analyses included χ 2 tests for comparing groups and t-tests for comparing means. A logistic regression model was constructed to determine the independent predictors of having had a test for prostate cancer and included: (i) age, (ii) area of specialty (in the doctor's survey only, general practitioner (GP) vs other specialty), (iii) marital status and (iv) education level attained (in the CS only, primary, secondary or tertiary). Cognitive features were also included in the model, and comprised knowledge and attitudes associated with prostate cancer testing. The results of the analyses were considered statistically significant when P < 0.05.
RESULTS
The demographic characteristics of the MD who participated are shown in Table 1 . GPs represented the largest specialty (42%), followed by surgery (16%), internal medicine (4%), urology (3%) and rehabilitation (3%). The CS was skewed towards the older age groups, with men ≥ 60 years of age accounting for 59% of respondents (as opposed to 38% of MD). In addition, respondents were generally well educated (30% having completed a tertiary degree or higher) and 86% were married.
Knowledge of prostate issues
Overall, 55% of the CS, compared with 83% of MD, indicated correctly that prostate disease is 'sometimes' cancer (Table 2) . By contrast, just over one-quarter (27%) of the CS thought it was 'mostly' or 'always' cancer, compared to 1% of MD.
Both groups were asked their opinion on the general accuracy of prostate cancer tests for the detection of prostate cancer. Sixty-four per cent of MD indicated that tests were 'quite accurate', which was the statement we considered to be the most appropriate response. This figure compared to 40% in the CS (χ 2 = 13.92; degrees of freedom (d.f.) = 1; P < 0.001). A significant number of people in the CS (40%) replied 'unsure/can't say' on the accuracy of the tests, compared to 10% of MD. Community respondents who believed tests to be 'quite' or 'very' accurate were significantly more likely to have been tested for prostate cancer themselves (χ 2 = 13.28; d.f. = 1; P < 0.001). MD who believed the tests to be 'quite' or 'very' accurate were not more likely to be tested for prostate cancer themselves (χ 2 = 1.44; d.f. = 1; P = 0.23). Significantly more older men (aged ≥ 60 years) in the CS (68%) believed prostate tests to be 'quite' or 'very' accurate, compared to 57% of MD in the same age group (χ 2 = 5.16; d.f. = 1; P = 0.02).
Attitudes towards prostate cancer testing
Both groups were asked, 'How often do you think men of your age should have a prostate cancer test?' Overall, 55% of MD believed men should be tested at least every 2 years, compared to 68% of men in the CS (χ 2 = 11.23; d.f. = 1; P < 0.001).
Men ≥ 60 years of age in the CS were significantly more likely to specify the need for regular testing (71%), compared to 58% of MD in the same age group (χ 2 = 7.39; d.f. = 1; P < 0.001). No differences were found in the < 60 years age group.
Men in both samples who had been tested previously were more likely to be supportive of men being tested every 2 years or less (CS 83% vs MD 75%; χ 2 = 13.2; d.f. = 5; P < 0.02). MD who had been tested for prostate cancer were significantly more likely to believe that men should be tested for prostate cancer on a regular basis (χ 2 = 7.19; d.f. = 1; P < 0.05).
Testing experience: male doctors Forty-five per cent of MD had been tested for prostate cancer in the past. Of that group, 56% had a PSA test by itself and 36% had a PSA in combination with a DRE (Fig. 1) . Testing experience: community sample
In the CS, 279 respondents (56%) had been tested for prostate cancer in the past (Fig. 1 ). Of these, 23% had a PSA alone, 39% reported to have had a DRE alone and 37% were a combination of PSA and DRE. Seventy-eight per cent of the results were reported as negative and 64% of tests were performed by GPs.
Having had a test varied with age (χ 2 = 22.75; d.f. = 4; P < 0.001), with the highest proportion (67%) in the 65-69 years of age group. The majority of tests (68%) had been performed in the last 12 months and this proportion was high across all age groups.
To assess the independent predictors of having had a test for prostate cancer, a logistic regression model was constructed, including: (i) age, (ii) marital status and (iii) education level attained (primary, secondary or tertiary) ( One-third of MD who had experienced a prostate test, compared with 29% of men in the CS, reported being 'somewhat' or 'very' worried while waiting for their results (Fig. 1) . This difference was not significant. Of those tested, over 80% of respondents in both groups reported that they were tested regularly (Fig. 1) . The main reasons why men in the CS were having tests included: (i) 'just to keep a check on it' (50%), (ii) because they were in the right age group (11%) and (iii) follow up after a positive result (16%). Similarly, the main reasons reported by the MD were (i) to keep a check on it (50%), (ii) to follow up a positive result (16%) and (iii) being in the right age group (11%).
Overall, 147 (55%) of MD (46% aged ≥ 60 years) indicated they had never been tested for prostate cancer, compared to 221 (44%) in the CS (39% aged ≥ 60 years). The major reasons that men did not have tests were: (i) they were not experiencing any symptoms of prostate disorder (MD 34%; CS 53%), (ii) they had not got around to it (MD 20%; CS 14.5%), (iii) controversy over the tests (MD 33%) and (iv) no particular reason (CS 11%).
Male doctors were compared with their colleagues who had never been tested. Those who had been tested at least once were significantly more likely: (i) to believe that men should be tested for prostate cancer on a regular basis (χ 2 = 9.39; d.f. = 1; P < 0.01), (ii) to believe that all men over 50 years of age should be screened for prostate cancer (χ 2 = 23.3; d.f. = 1; P < 0.01) and (iii) to be over the age of 55 (χ 2 = 9.26; d.f. = 1; P < 0.01).
Information provided and received
Overall, 30% of doctors who conduct prostate cancer tests reported that they use educational resources to assist their discussions with patients. Just over onethird (35%) of the CS reported that they were told of the limitations of the test, and 55% reported that they were given an adequate explanation prior to the test (Fig. 1) . Nearly two-thirds (65%) of CS respondents indicated that they were informed of their results personally by their doctor and 22% indicated that the doctor advised them over the telephone. The remaining 13% were informed through a variety of methods (i.e. by the doctor's receptionist or by letter) or were told they would only be contacted if there was a positive result.
Perceived messages about prostate cancer testing
Both groups were asked to identify what was the main message they had read, seen or heard on prostate cancer testing. MD reported that: (i) the test was controversial (24%), (ii) there was a need for men to have regular tests (18%), (iii) there was a query over the accuracy of the test (14%), (iv) early checking is important (12%), (v) they were unsure of relevance (11%) and (vi) there was confusion over screening (8%). CS indicated that: (i) there was a need for men to be tested regularly (52%), (ii) there was a need to have a test if symptomatic (17%), (iii) early checking is important (10%) and (iv) it is important to be aware of prostate disease (9%).
DISCUSSION
This study was undertaken to identify information that could enhance a public health campaign designed to address the issue of prostate cancer testing in the community. To our knowledge, no other study has compared a medical and a community group regarding their knowledge, attitudes and experience associated with prostate cancer testing.
In discussing these results, it is important to recognize the potential limitations of this research. Self-report measures can result in bias due to social desirability and, in the case of reported behaviours, selective recall. Consequently, the results must be interpreted with this in mind. Due to the goals and sampling frame, the results may not represent all medical practitioners who conduct or refer patients for prostate cancer tests. However, as the respondents were randomly selected and with the response rate achieved, we are confident that the respondents' answers were a reflection of attitudes and behaviours of MD. With regard to the CS, no information was collected on non-respondents, consequently selection bias could not be ascertained. However, given that the respondents were generally well educated and the majority were married, we are aware of potential bias in the sample.
Although there is no officially endorsed prostate cancer-testing programme in Australia, testing was prevalent in the community. Approximately 55% of men aged 50-70 years in Victoria have had at least one test for prostate cancer, which is consistent with other studies. 5, 11, 12 The study revealed that men in the CS had a general awareness about prostate cancer without possessing detailed information. Men who held positive attitudes about prostate cancer testing were more likely to have been tested for prostate cancer. In addition, men who had knowledge about prostate disease were more likely to have been tested. Only 30% of doctors reported using educational resources to explain prostate cancer testing and only one-third of the CS The results indicated that, while a substantial proportion of testing may be done as an investigation of urinary symptoms among patients, there appears to be a significant number of tests done on asymptomatic men. It also appears that many of the tests are undertaken without men being fully informed of the potential consequences. Another important finding was that, while there is basic knowledge about the issues associated with prostate cancer among men in the community, this knowledge level appeared insufficient to make fully informed decisions in relation to their own tests for prostate cancer.
The benefits of screening are possible and plausible but, at present, uncertain. Although the benefits are uncertain, this does not mean that men should not be allowed to be tested if they understand the issues involved. It is important that consumers understand the issues in a way that will permit them to participate in decisions about whether or not to have a PSA test or, if symptomatic, in decisions about the way their condition is managed. Men who simply follow professional advice could be managed in vastly different ways, depending on which doctor they consult.
The AHTAC 1 and the Urological Society of Australasia do not support population screening unless, and until, the results of randomized controlled trials show positive benefits and until resources are in place for doctors to provide patients with objective information on the risks and benefits of prostate cancer intervention. Men being offered, or requesting, a PSA test must be fully informed of the limitations of the tests currently available and of the possible further diagnostic and treatment choices that they may face should they decide to proceed with an initial test. This offers a 'pro-choice' platform, which allows doctors to offer testing with balanced information so that men in the community have a solid basis on which to accept or reject their doctor's recommendations.
Prostate cancer testing is also problematic from the practitioner's perspective. There are constraints that do not allow medical practitioners to spend a great deal of time with patients explaining the arguments for and against prostate cancer testing. In addition, medical practitioners are rightly concerned about the medico-legal implications if they do not test someone for prostate cancer and the cancer eventually develops.
To improve informed choice, the dissemination of information could be incorporated with populationbased health promotion initiatives that promote a broad approach to men's urological health issues. Information on the issues surrounding prostate cancer -such as a more realistic understanding of the low risk of dying from prostate cancer (which is dependent on age at diagnosis and comorbidities, stage and grade of tumour), the associated burdens and the uncertainties linked with prostate cancer testing and treatments -has been shown to reduce the desire for PSA screening. 13 Information about the prostate gland, its location, normal function and associated disorders, is required. There is a need to address the issue of the accuracy of prostate cancer tests, given that men have widely varying beliefs about their accuracy. There is also a need to challenge the belief among men in the community that 'every man needs to be regularly tested for prostate cancer' and to describe what the various prostate cancer tests actually measure. It is also necessary to resolve confusion about the differences between benign forms of prostate disease and prostate cancer.
The present study identified a number of major factors that impact a on man's decision to have a prostate cancer test, such as: (i) the attitudes of the doctor involved, (ii) the impact of media coverage about the 'need to be tested' and (iii) the desire for 
